$CGON

POST LEONARD E sold $73K of CGON

POST LEONARD E sold 1,000 shares of CG Oncology, Inc. (CGON) at $72.98 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · POST LEONARD E
Published Sep 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGON
Neutral
medium confidence
Mentioned
$CGON
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGONNeutralLow
01

Why it matters

The filing provides a transparent view of insider activity but offers little actionable insight.

02

Market read

Minor insider sale with limited market impact.

03

What to watch

Potential upcoming financing needs or strategic shifts not disclosed in the filing.

Relevance 2/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$CGONNeutralMedium confidence
Context

Director Leonard Post sold 1,000 shares for $72,980 via a 10b5-1 plan, reducing his stake to zero.

Expected impact

negligible impact on price

Evidence & confidence

A $73K sale by a director is a routine liquidity event with no material change in ownership.

Market effects

None; the sale does not affect the oncology sector broadly.

None; limited to CG Oncology shareholders.

None; the transaction is company‑specific and small.

Counterpoint

If the director is exiting due to undisclosed concerns, the stock could face downside pressure.

Key entities

  • CG Oncology, Inc.

    Biotech firm listed on NASDAQ under ticker CGON.

  • Leonard E. Post

    Insider who sold his entire shareholding.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGONMed

CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology (NASDAQ: CGON) reported Q2 2026 results for the quarter ended June 30, 2026, with net loss of $79.1 million, or $0.90 per share. Cash, cash equivalents and marketable securities were about $1.0 billion, funding operations through 2029. The company said PIVOT-006 topline data are expected soon, and a BLA for HR BCG-unresponsive NMIBC is expected in Q4 2026.